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Summary
Mutagen treatment of mouse tumor cell line P815 produces turn - variants that are rejected by
syngeneic mice because they express new transplantation antigens. These turn - antigens are rec-
ognized by cytotoxic T lymphocytes (CTL) but induce no detectable antibody response. By trans-
fecting P815 cell line P1.HTR with DNA of turn- variant P198, we obtained transfectants ex-
pressing turn - antigen P198 that could be identified on the basis of their ability to stimulate
anti-P198 CTL. This was repeated with DNA of a cosmid library derived from variant P198,
and a cosmid carrying the sequence encoding antigen P198 was recovered from a transfectant.
GeneP198is 3 kb long and contains eight exons. It shows no homology with previously identified
turn - gene P91A, nor with any gene presently recorded in the data banks. The long open
reading frame codes for a 23.5-kD protein. The antigenic allele of gene P198 differs from the
normal allele by a point mutation located in exon 7. This mutation causes an Ala to Thr change,
and was shown by site-directed mutagenesis to be responsible for the expression of the antigen.
An 11-amino acid synthetic peptide covering the sequence surrounding the turn - mutation ren-
dered P815 cells sensitive to lysis by anti-P198 CTL. The homologous peptide corresponding
to the normal sequence of the gene did not, but it was able to compete for binding to major
histocompatibility complex molecule Kd. We conclude that turn - mutation P198 generates a
new epitope recognized by syngeneic T cells. As observed with gene P91A, we found that a
fragment of gene P198 that contained only exons 3-7, cloned in nonexpression vectors, trans-
ferred efficiently the expression of the antigen.
T
ransplantation antigens, such as minor histocompatibil-
ity antigens, tumor-specific transplantation antigens
(TSTA)t, or male-specific antigen H-Y often induce cytolytic
T cell responses, but do not elicit antibody responses (1). These
antigens can therefore not be isolated by immunoprecipita-
tion like the major histocompatibility antigens, and theirstruc-
ture and genetic origin have remained largely unknown. We
have developed a gene transfection approach aimed at iden-
tifying directly the genes that code for this type of antigen,
and we have applied it to the turn - transplantation antigens
that arise on mouse tumor cells when they are treated with
mutagenic agents.
In vitro mutagen treatment of mouse tumor cell lines
generates at very high frequency stable immunogenic vari-
r Abbreviation used in this paper. TSTA, tumor-specific transplantation
antigen.
ants that are rejected by syngeneic mice (2-4). Since they fail
to form tumors, these variants have been named turn - , as
opposed to the original turn + cell, which forms progressive
tumors. Most turn - variants express new transplantation an-
tigens not found on the turn+ cell. The existence of these
turn - antigens has been demonstrated in vivo by crossim-
munization experiments and in vitro with CTL (5, 6).
A large number of turn - variants have been derived from
mastocytoma P815, a tumor induced in a DBA/2 mouse with
methylcholanthrene (7) . For most P815 turn - variants,
stable CTL clones have been obtained that show a strict
specificity for the immunizing variant and thus define one
or several turn - antigens (8). The turn - antigens defined by
CTL are relevant to the rejection of the variants, as shown
by the correlation between the loss of these antigens and the
reversal of the turn- phenotype (9, 10). The diversity of
turn - antigens is considerable: the analysis of 15 P815 turn -
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of them with no evidence of crossreactivity (11). This large
diversity is reminiscent of that observed with TSTA expressed
by tumors induced with chemical carcinogens (12).
To clone the genes that determine the expression of turn -
antigens, we have developed an approach based on gene trans-
fection and detection of antigen-expressing transfectants with
CTL, since no antibodies are available (13) . By transfecting
P815 turn+ cells with a cosmid library prepared with the
DNA of a cell expressing turn - antigen P91A, we have ob-
tained transfectants expressing this antigen, and from these
transfectants, we have recovered a cosmid carrying the en-
coding gene (14). This enabled us to obtain the sequence of
the gene coding for turn - antigen P91A (15) . This gene
shows no significant homology with any of those presently
reported in data bases. It codes for a 60-kD protein that does
not appear to be localized at the cell surface, an observation
in line with the demonstration that antiinfluenza CTL recog-
nize MHC-bound peptides corresponding to viral proteins
that remain inside the cell. A mutation that causes the ex-
pression of the antigen is located in an exon and appears to
be the only difference between the normal and the antigenic
allele. A short synthetic peptide corresponding to the coding
region located around the turn - mutation makes P815 cells
sensitive to lysis by anti-P91A CTL. A major consequence
of the turn - mutation is the creation of a strong aggretope
enabling this peptide to bind to H-2 molecule Ld (15).
Whereas the results obtained with turn - antigen P91A
provided a first clarification about the nature of this type of
antigen, there remained several questions. Would our cloning
approach provegenerally applicable? Wouldthe direct gener-
ation of new antigenic peptides by point mutations prove
to be a major immunogenic mechanism? And finally, would
the genes coding for other turn - antigens resemble P91A
or would they be completelyunrelated? To answer these ques-
tions we set out to clone other turn - antigens. We present
here the results obtained with one of them.
Materials and Methods
Cells.
￿
The derivation from mastocytoma P815.X2 ofclonal line
PI (turn+) and of turn - variant P198 by treatment of P1 with N-
methyl-M-nitro-N-nitrosoguanidine was described earlier (7).
Repeated cycles of transfection of PI ensured the selection of the
highly transfectable cell line P1.HTR.tk - , which has a transfec-
tion efficiency of 10-4 with the calcium phosphate precipitation
method (16). DAP L cells (H-2k) and transfected derivatives T111
(expressing H-2L') and T483 (expressing H-2Dd) were a gift from
K. Ozato (17). DAP-T191 clone (transfected with the K° gene) was
described previously (15). The cultures were maintained in DME
(Gibco Laboratories, GrandIsland, NY) containing 10% FCS (Gibco
Laboratories) and incubated in tissue culture flasks at 37°C in air
containing 8% CO2.
CTL Clones. CTL clones CTLP198:6 and CTLP91:6 show
strict specificity for turn - variants P198 and P91, respectively.
Their derivation and their long-term culture conditions were de-
scribed previously (8).
Transfection.
￿
For the transfection of genomic DNA, we used
the method described by W61fe1 et al. (13). Briefly, groups of 5
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x 106 P1 .HTR tk- cells were incubated for 20 min at 37°C in
preformed calcium phosphate DNA precipitate containing genomic
DNA (60 wg) mixedwith plasmid pSVtkneoO (61~g) as selective
marker (18). The following day, the medium containing the precipi-
tate was replaced by fresh medium. Selection of the transfected cells
was carried out 1 d later by incubating 1.6 x 10' cells of each
group in 80 ml of medium containing 1.5 mg/ml of the neomycin
analog G418 (geneticin; Gibco Laboratories). To estimate the
number of independent transfectants, 106 cells were plated for a
colony test in 5 ml medium containing 0.4% bactoagar (Difco
Laboratories, Inc., Detroit, MI) and 1.2 mg/ml of G418. A correc-
tion was made for the cloning efficiency of P815 cells in agar, which
is -0.3.
The same procedure was applied for the transfection of the c2RB
cosmid library. Groups of 5 x 106 P1.HTR cells were transfected
with 60 Ag of DNA of the amplified library and 2 Ag of cosmid
pHMR272 coding for the resistance to hygromycin B (19). The
transfectants were selected after 48 h in a medium containing 350
,ug/ml of hygromycin B.
Transfections with isolated plasmids were performed by treating
the cells with 10 frg of plasmid DNA and 2 Rg of pSVtkneoo.
Screening ofTransfected Cells. For the detection of transfectants
expressing antigen P198, we used the method described in W61fel
et al. (13). 8 d after selection, the drug-resistant transfectants were
separated from the dead cellsby centrifugation on Ficoll-Paque (Phar-
macia Fine Chemicals, Piscat) before being plated on 96-well round-
bottomed microplates at 30 cells per microculture of 200 Al. De-
pending on the number of independent transfectants, 1-5 plates
were prepared for each group. After 5 d at 37°C, each well con-
tained N3 x 104 cells: aliquots of 20 Al were transferred to dupli-
cate wells that were incubated at 30°C. The following day, the
master plates were centrifuged, and the cells were resuspended in
200 Al of a medium containing 1,000 CTILP198:6, 106 irradiated
DBA/2 feeder splenocytes, 10 U/ml rIL2 (a kind gift of Walter
Fiers, State University of Ghent, Belgium), and HAT (10-° M
hypoxanthine, 3.8 x 10' M aminopterin, 1.6 x 10-5 M 2-deoxy-
thymidine) to prevent the proliferation of the P1.HTR tk-
stimulatory cells. After 5 d, the proliferation ofthe CTL was evalu-
ated. For the plates whereproliferating microcultures were observed,
aliquots of 100 Al of all the wells were transferred to a separate
plate containing 2,000 "Cr-labeled P198 cells per well. Chromium
release was measured after 4 h. The duplicatesof the positive wells
were subdoned by limiting dilution so as to obtain 150-300 clones.
After 5 or 6 d, theseclones were screened for lysis by CTLP198:6
in a visual assay followed by a chromium release test for final
confirmation.
Visual Lysis Assay.
￿
Aliquots (10' cells) from individual clones
were incubated either alone or together with 2 x 104 CTLP198:6
in DME with 10% FCS in 96-well round-bottomed microplates.
1 d later, the plates were examined for the presence of surviving
tumor cells (9).
Assayfor Cytolytic Activity.
￿
The protocol used has been previ-
ously described (6). CTL and 2,000 "Cr-labeled targets were in-
cubated at various ratios in 96-well conical microplates in a final
volume of 200 pl. Chromium release in the supernatant was mea-
sured after 4 h.
Cosmid Libraries. Cosmid arms of c2RB were prepared by
cleavage with Smal and treatment with calfintestinal phosphatase,
followed by digestion with BamHI (20). Genomic DNA was par-
tially digested with Sau3AI (0.05 U/pg) for three time points and
centrifuged on a NaCl gradient (21). Fractions containing DNA
fragments of 35-50 kb were ligated to c2RB arms overnight at
14°C with T4 DNA ligase (Amersham Corp., Arlington Heights,IL) as described previously (14) . The ligation product was pack-
aged into A phage components (Gigapack Gold, Stratagene) and
titrated on Escherichia coli ED8767 with ampicillin selection . An
average of 8 x 101 Amp' colonies/ug of insert was obtained . The
amplification of groups of 10 1 cosmids of the library was per-
formed as described before (14) . DNA of each amplified cosmid
group was extracted and purified on CsCl gradients .
Cosmid Rescue.
￿
1 ug of high molecular weightDNA of trans-
fectants expressiong P198 antigen was directly packagedinto Xphage
components (Gigapack Gold, Stratagene) . Theproductwas titrated
onE . coli ED8767 with ampicillin selection (14) . Groups ofcosmids
were amplified . DNA was extracted and purified on aCsCl gradient .
DNA Sequencing andHomology Search .
￿
Restriction fragments
of cosmidsC198.3 .1 and C1.198.1 were subcloned into M13 vectors
as described (15, 22-24) . Nucleotide sequences were determined
by the Sanger's dideoxy chain termination method using the en-
gineered form oftheT7DNA polymerase (Sequenase Kit ; United
States Biochemical Corp., Cleveland, OH). The computer search
for sequence homology was done with programFASTN, with K-
tuple parameters of three and six (25) . EMBL database release 18
(March 1989) and Genbank release 60 (June 1989) were used .
mRNA Analysis.
￿
cDNA libraries were constructed in Xgt10
(14, 26 ; Amersham cDNA synthesis system). Northern blots were
prepared andhybridized as described (15) . S1 nuclease mapping and
RNAse protection assay were performed following the protocol
described by Ausubel et al . (27) .
The rapid amplification of the 5' end of P198 mRNA was per-
formed as describedby Frohman et al . (28) . Theprimer used for
the synthesis of the cDNA was 5'-ACACCTTGAGGCGCTCC-3'
(position 3557-3541) . For the amplification, we used 5'-AGCCT
GGCCTCTCTTGG-3' (position 3535-3519) as 3' primer, andthe
primers describedby Frohman et al . as 5' primers . The amplified
productwas cloned inM13mp18 using the Sall site ofthe 5' primer
and a SphI site located in the P198 sequence at position 3501 ;
resulting clones were sequenced .
Site-directedMutagenesis.
￿
Themutagenic oligonucleotide 5'-CCA-
GAGTGGTTGTCACTGCC-3', synthesized by Eurogentec (Liege,
Belgium), was used to modify the sequence of the Bg1II-Bg1II frag-
ment of cosmid C1.198 .1, which was cloned in bacteriophage
M13tg130 following the method of Nakamaye and Eckstein (29;
Amersham site-directed mutagenesis system) .
Peptide Production andAssay.
￿
Peptides were synthesized by G.
Corradin (Ludwig Institute for Cancer Research, Lausanne Branch,
Institute of Biochemistry, University ofLausanne), using Merrifield's
solid-phase method (30) .
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For the assay on P815, microwells received various concentra-
tions of the peptide diluted in 50 Etl of DME and 2,000 "Cr-
labeled target cells in 50 P1 . After 15 min at 37°C, 20,000 CTL
P198:6 were added in 100 /.1 of medium . The cells were incubated
for 4 h at 37*C before the chromium release was measured .
Results
P198 is a turn- variant obtained after mutagen treatment
ofP1, a clonal cell line derived from mouse tumor P815 (7) .
By restimulating in vitro spleen lymphocytes ofDBA/2 mice
that had rejected turn - variants, stable CTL clones were
produced that recognized either all P815 cells or only the
immunizing variant (8) . Thus, CTDP198:6 was obtained that
lysed P198 but neither PI nor other turn - variants derived
from P1 (Fig . 1) . This CTL defined turn- antigen P198 .
Transfection ofturn - Antigen P198.
￿
We demonstrated ear-
lier that the expression of turn- antigen P198 is dominant
in (P1 x P198) somatic hybrids (31) . Therefore, we used gene
transfection as a first step in the cloning of the gene encoding
this antigen . Following the approach that had ensured the
isolation of transfectants expressing turn - gene P91A (13),
we transfected withDNA of turn- variant P198 the highly
transfectable clone P1.HTR, which had been derived from
PI (16) . For the detection of transfectants expressing antigen
P198, we used a test relying on stimulation ofCTLP198:6 .
In reconstruction experiments, microwells were seeded with
1,000 of these anti-P198 CTL and with a mixture of 2 x
103 P198 cells and 6 x 104 P1.HTR cells, which do not ex-
press antigen P198. A significant proliferation of the CTL
was observed visually after 5 d, and it could be measured
by testing the lytic activity ofthe microcultures against P198
(Fig. 2A) . This indicated that identification oftransfectants
expressing antigen P198 should be feasible by testing the trans-
fected cells by pools of 30.
A total of 42 groups of 5 x 106 P1.HTR cells were
cotransfected with DNA of variant P198 and plasmid
pSVtkneoO, which confers resistance to geneticin. Each group
produced 300-1,500 independent geneticin-resistant transfec-
tants. After selection in geneticin, the transfected populations
were amplified and distributed by pools of30 cells into 100-500
wells, according to the estimated number of independent trans-
Figure 1 .
￿
Antigens recognized by DBA/2
CTL on turn- variant P198 and on P815 turn*
cell P1 . P815 cells express four putative TSTAs
recognized by DBA/2 CTL (44) . The cytolytic
activity of CTL clone P198 :6 (anti-P198), di-
rected against turn- antigen P198, and that of
CTL clone P35:10 (anti-P815), directed against
P815 antigen B, was measured by chromium re-
lease after an incubation of 4 h .fectants present in the population . These microcultures were
allowed to grow to 3 x 104 cells and, at this point, aliquots
were transferred to duplicate wells. 1,000 anti-P198CTL were
then added to each well and, 5 d later, the proliferation of
CTL in the microcultures was evaluated visually. For those
plates where proliferation was observed in some wells, the
lytic activity of all the microcultures was tested on "Cr-
labeled P198 cells. Positive microcultures were observed in
2 of the 42 groups of transfectants (Fig . 2 B) . This cor-
responded to a frequency ofone antigen-expressing transfec-
tant per 13,000 drug-resistant transfectants . The duplicates
of the positive microcultures were subcloned, and the clones
were tested for their sensitivity to the anti-P198 CTL with
a visual assay. Antigen-expressing clones were found, and their
lysis byCTLP198:6 was observed to be comparable with that
of P198 (Fig . 3) .
Isolation of a Cosmid Transferring Expression of Antigen
P198 . Because we had been unable to recover turn - gene
P91A on the basis of its linkage to the cotransfected plasmid,
and because a cosmid retrieval approach had worked readily
for this gene, we applied the cosmid approach to P198 . A
library of 4 x 105 cosmids was constructed with DNA of
variant P198, which was partially digested with Sau3AI and
ligated to vector c2RB (14) . The library was divided into
four groups of 105 independent cosmids that were amplified
by a factor of 10 1 to obtain enoughDNA for transfection .
We applied the transfection and detection procedure that had
Figure 2 .
￿
(A) Stimulation of CTLP198 .6 with populations con-
taining a minority of P198 cells. Microcultures contained 1,000 CTL
and either no stimulating cells, 2,000 P198 .aza` cells, 2,000 P198 .aza`
and 60,000 P1.HTR.tk- cells, or 60,000 P1.HTR.tk - cells . They
were incubated for 5 d in medium supplemented with IL-2 and HAT.
The lytic activity of the microcultures against P198 was then mea-
sured in a 4-h "Cr release assay. Each point represents the lytic ac-
tivity of a single microculture .
￿
(B) Identification of microcultures
containing antigen-expressing transfectants . Groups of Pi.HTR.tk -
cells were transfected with DNA of P198 and pSVtkneoo . After drug
selection, each group of transfectants was distributed in 96-well
micro~lates at 30 cells per well . When the microcultures reached ti3
x 10 cells, 1,000 CTLP198 :6 were added to each well. After 5 days,
the lytic activity of the microcultures against P198 was measured in a
4-h "Cr release assay. The results obtained with,positive plates found
in groups 4 and 5 are shown . Each point represents the lytic activity
of a single microculture .
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￿
Lysis of PLHTR genomic transfectants (P198T1 and
T2) and of control targets by anti-P198 CTL clone CTLP198 :6 in a
4-h "Cr release assay. Lysis by CTLP91 :6, which is directed against
unrelated turn - antigen P91A, is also shown .
been used with genomic DNA . Each cosmid group was
cotransfected with selective plasmidpHMR272, which codes
for hygromycin resistance. Transfectants expressing antigen
P198 were obtained with three of the four cosmid groups.
A total of five independent transfectants were obtained.
The DNA of each transfectant was extracted and pack-
aged directly withX phage extracts; all produced cosmid popu-
lations, which were amplified and transfected . Only those .
cosmids derived from transfectant P198TC3 produced trans-
fectants expressing the antigen, and the frequency was very
low (1/4,500) . A Southern blot analysis revealed that theDNA
ofone of these secondary transfectants contained only a small
number ofintegrated cosrnids . We therefore used thisDNA
for a second direct packaging experiment, and this time, we
obtained a cosmid population that transferred the P198 pheno-
type at high frequency : >50% ofthe drug-resistant transfec-
tants expressed the antigen. This cosmid population consisted
of only three different cosmids . Two of them transferred the
expression of antigen P198, and a 43-kb cosmid C198.3.1
was selected for further analysis .
A 1.2-kb Fragment Transfers the Expression of Antigen
P198 . A restriction map of cosmid C198'.3.1 was obtained
(Fig. 4) . A 14-kb XbaI restriction fragment produced trans-
fectants that were lysed by anti-P198 CTL . Further diges-
tion,of this fragment produced a 5-kb HindIII fragment and
eventually a 1.2-kb Bg1II-HindIII fragment that transferred
the expression of the antigen (Fig . 4) .
Expression ofGene P198 .
￿
The 5-kb HindIII fragment that
transferred the expression of antigen P198 was used to probe
a Northern blot prepared with poly(A) + RNA isolated
from variant P198 . A single band of 0.7 kb was observed.
A band of similar size and intensity was revealed on a parallel
lane containingRNA of P1, which does not express the an-
tigen . The expression ofthe antigen by variant P198 is there-
fore not due to the activation of a silent gene.
Structure ofGene P198 .
￿
Using the 1.2-kb Bg1II/Hind1II
fragment as a probe, we screened 3 x 105 phages of a Xgt10
cDNA library derived from P1 . 15 positive clones were found .
We sequenced the longest completely processedcDNA, which
comprised 649 bases before the polyadenylation site. To en-
sure that we had the complete 5' end sequence of the mes-
sage,we applied a modification of the polymerase chain reac-
tion developed by Frohman et al . (28) . This indicated that
P198.T1 P1 98.T2 P198 P1.HTRthe full-length processed mRNA contains 653 bases . Com-
parison of the cDNA sequence with that of cosmid C198.á.1
recovered from the transfectant indicated that this cosmid
lacked the 3' end of gene P198 . A cosmid that appeared to
carry the complete gene was identified in a library derived
from PI by using the 1.2-kb Bg1Il/HindIII probe. The com-
plete sequence of the gene was obtained by sequencing over-
lapping fragments of the two cosmids .
Gene P198 is -3 kb long and comprises eight exons bor-
dered by consensus splicing sites (Fig. 5) . The longest open
reading frame present on the P198 cDNA sequence codes for
a 23.5-kD protein of203 amino acids. The complete sequence
of the gene is shown in Fig . 6 . The cap site indicated there
corresponds to the 5' end of the cDNA clones expanded by
polymerase chain reaction . It was confirmed by S1 nuclease
and ribonuclease protection assays . A GATAA sequence
showing some homology with the consensus TATA box and
two GC-rich regions are located, respectively, 33, 204, and
263 nucleotides upstream of this site. The open reading frame
starts 18 nucleotides after the cap site at an ATG codon sur-
rounded by a consensus initiation sequence (32) . It terminates
at a TGA codon located in exon 8 . A short 3' untranslated
region (27 bases) contains a polyadenylation signal located
20 bases before the poly(A) addition site.
Petl -
BamHl
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Restriction map of C198 .á .1 and iden-
tification of fragments transferring the expression of
antigen P198 . Restriction fragments of C198 .á .1,
which were all cloned in pUC vectors with the ex-
ception of the 14-kb Xbal fragment, were cotrans-
fected into P1.HTR with pSVtkneoß . The drug-
resistant cells were selected, and clones were tested
for lysis by CTLP198 :6 in a visual assay . Regions
containing sequences of the cosmid vector are
marked a and b . Subsequent analysis revealed that in
this cosmid, gene P198 is interrupted at position
4176 (see Figs . 5 and 6), immediately before the
Hindlll site of the cosmid, which is located at the
end of the 1.2-kb Bglll-HindIII fragment .
The sequence of gene P198 shows no homology with pre-
viously cloned turn - gene P91A, nor with any gene
presently recorded in data banks .
Identification of a Point Mutation in the Antigenic Allele of
P198. Southern blot analysis was performed on P1 and P198
DNA with two probes derived from gene P198 . Probe a,
which comprised exon 1 (see Fig. 5), hybridized to a single
homologous fragment on P1 and P198 DNA . Probe b, which
comprised only exon 7 (see Fig . 5), hybridized to several
different bands, suggesting that several genes contain homol-
ogous sequences. For both probes, no additional band was
observed in the P198 lanes, and all the bands of PI and P198
coincided . This makes it unlikely that a rearrangement of
the gene was responsible for the expression of the antigen .
The 1.2-kb Bg1II/HindIII transfecting fragment of cosmid
C198.á.1 comprised exons 3-7 . The sequencing of the ho-
mologous fragment from the cosmid identified in the P1 li-
brary revealed a point mutation in exon 7 : the guanine res-
idue located in position 4114 in the normal allele was replaced
by an adenine in the antigenic allele. This transition directs
a change from alanine to threonine in the protein encoded
by the long open reading frame .
By site-directed mutagenesis, we demonstrated that this
mutation was responsible for the expression of the antigen .
Figure 5 .
￿
Structure of gene P798. The eight
exons are represented by black boxes. The position
of the point mutation found on the antigenic allele
is indicated by an asterisk . Restriction sites are indi-
cated by arrows. Probes a and b used for the anal-
ysis of Southern blots are shown .GAACGGAGAAGAGCGATCCCTTCAAATATJCGGCTGCGGCTTGGCCGGCATTGTACGGCTGAAGCCGCTCCGAAACCCACGTGACATCCCGCCCCGCA 1465
CAGTCATGGCCGCCAAGAGCCAACTCAGGCGACATTCTGATTGGACAAAATAAAAATGGCCCGCCTCGATAGACGCGCACTCACCGCTTCGACCAATTA 1564
GAAGACGGAAACTCTTCGGTTCGAGCCGTCTGCGTCACTTCCTCCGACCCCTGCAGCAAGGglalWAAACCCTGCGAAAAGACCTCCTCCTTT QC 1659
CCAGGCGGCTGCCGAAGATG GCG GAG GGG CAG
￿
GTTCGGACTCTGCGCGCGCCGGGCGGTGTGGGGTCGGGTGGGTGCCAGGCGGGACGCAGT 1751
Met Ala Glu Gly Gln
GAGGGGCCACTGCTCCCCGCCGCTTGTGCGATGGGACTTAGCAAACGTCTCACGCGAGGGGACTGTGTAACGGGCGTAACAAGCCGCGGCTGCCTAGGT 1850
ATGGGGCGATGGAAATGCAGCGGGTTTTCTGGGGAAGACGGGAGTGGGGCTGGGGTTCCAACACCAGAAACAACTTTTACAGGTTGTAATCTCAGGCGT 1949
TGGGGTGCGGGGAGCTTGCAATCTCTCATGCCTGGTGTATGTATGTAAGATAAGGAGAAACTGTCGCAGGCTCCTGCTTTGCATGACTTTAGGGCACCG 2048
GATTCCTGTAACATCTGATCTGAAGGCTTGTAGGCCTTTTGAGGGTGTTTTCGGTGTTCTTCAGAATTGGGGAGATTGATAAGACAGACTTTAAATATT 2147
ACTTATTCACCCGACTGAAGCAGGAACCTCTTCATTTTGAGGCTGGTCAGGAATTGCCTGTACCTTCCTCCTGACTTTAGATTCCTTGACAGGTTGCTG 2246
CTCAGGAAGTAAATGGTGCTGTTTGGGACAGTTTTGCCCTTTAAAAAGAACTTGGGAAGTTCCGGAGACCCTCCAGTAACAGCAATAAACAGGGTGGCT 2345
GTGGAATGGGCTTCTTCTGTAGTTTGGGTTGGGATGCAGACATGTGCCTCCATGCCTGAGACGGGATTTAGCTTTGTAATCCAGTCTGCACTGCTCAGA 2444
ATCACAGGACGATGTGTGCTTAGCTAAATCGGGTTCTTTTGAGTGATATAAGAAAGGTTCTGCTTGAGCATCTGAGGATCCCAGCTATCCTGGGATTTG 2543
AGGCCTGGAAGGGTTAAATGAAGTTCCATTTTAAAAAATCAACTTATATACACAATAGGAATCCTATGCCTGCTGAGGCTTTGTTAGTACTATAGTGGC 2642
CCTTTGGGACACTTGCTTCATCTGGGTAGTAGGCATCCTGACGGGTTGCTAACCTGGAATAGGGGAAGCCAAACTGTTTCCTAAGCATTCTTGTTTCCA 2741
CAG OGTT CTG GTA TTG GAT GGC CGA GGC CAT CTT CTT GGC CGC CTG GCG GCC ATT GTG GCC AAG CAG GTA CTT 2813
Val Leu Val Leu Asp Gly Arg Gly His Leu Leu Gly Arg Leu Ala Ala Ile Val Ala Lys Gln Val Leu
CTG G
￿
GTAAGTTTCATTCACCATTTACCTTTGCCTGGGAGTCCATGATCAGCAACACTCACCATCTTTCGTTTGAGTCTCACGACTGTGAGATCAA 2908
Leu
CCCATGCACCGCTCTGAGACTCGCCAGCCCCTGCTTTCTTGGGACCCCTGGCCTAAAAATACTTTTGGAGCAAGAGATCTCAAGAGGCTTTGCTGACTA 3007
ACTCCAACTCCCTGTTAACTCTAG OGC CGG AAG GIG GTG GTC GTA CGC TGT GAA GGC ATC AAC ATT TCT GGA AAC TTC 3084
Gly Arg Lys Val Val Val Val Arg Cys Glu Gly Ile Asn Ile Ser Gly Asn Phe
TAC AGA AAC AAG T GTGAGTTAGGGCTGGGGCAGTGGTCTTCAGGCGGGCTGTTGCCTTGCTCCTGGACAAGCAGGCATTCTGCTCTGCTCTTG 3177
Tyr Arg Asn Lys
GGTCCAAGGGTGCCTCACATACTTGTCTGACAG OTA AAG TAT CTG GCC TIT CTC CGG AAG CGG ATG AAT ACC AAC CCC TCC 3257
Leu Lys Tyr Leu Ala Phe Leu Arg Lys Arg Met Asn Thr Asn Pro Ser
CGA GGC CCC TAC CAC TIC CGA GCC CCC AGC CGC ATT TTC TGG CGC ACT GTG CGA G GTGAGTTGGTGACATGTAGGACAG 3336
Arg Gly Pro Tyr His Phe Arg Ala Pro Ser Arg Ile Phe Trp Arg Thr Val Arg
Figure 6.
￿
Sequence of gene
P198. The numbering of the nu-
cleotides corresponds to the scale
of Fig . 5 . The exons are numbered
from 1 to 8 . A possible TATA box
and two GC-rich regions located
before the first exon are under-
lined . The location of the point
mutation (A in the antigenic allele
instead of G in the normal allele
in position 4114) is indicated by an
asterisk . The sequence of antigenic
peptide P198- .14-24 is boxed. The
polyadenylation signal and the
start of the poly-A tail are indi-
cated. The amino acid sequence
corresponds to the long open
GAGAAGCAACCGCTCTGACATGTGTCTTTTCACACCACAG OAGG TTA CGG AAA CAG GCA GAA AAG AAT GTG GAG AAG AAA ATC 4303
￿
reading frame. This sequence has
Arg Leu Arg Lys Gln Ala Glu Lys Asn Val Glu Lys Lys Ile
￿
been submitted to the EMBL/
TGC AAG TTC ACA GAG GTC CTC AAG ACC AAC GGA CTC CTG GTG TGA ACCCAUWGACTGTTTGCCTCA
￿
TGCCTGCCTGGC 4384
￿
GenBank Data Library and has the
Cys Lys Phe Thr Glu Val Leu Lys Thr Asn Gly Leu Leu Val ire
￿
accession number X51528.
GGTAGGCTCTGGCAGCTTGTGATGAGACATCTCCCACTCATGTTCGAGTTGCTCGACTATGAGATGACTCTACATGCACTACCATCTGAGGCTGTTCTA 3435
GCCCTTGCCCTGGGGTCAGACGGGGTTCTCAGCACCTCTGATGAGGCCCGCTGTTACCCCCACAG OGC ATG CTG CCC CAC AAG ACC AAG 3523
Gly Met Leu Pro His Lys Thr Lys
AGA GGC CAG GCT GCC CTG GAG CGC CTC AAG GTG TTG GAT GGG ATC CCT CCA CCC TAT GAC,AAG
￿
GTGAGCCTTGCAA 3599
Arg Gly Gln Ala Ala Leu Glu Arg Leu Lys Val Leu Asp Gly Ile Pro Pro Pro Tyr Asp Lys
GCCTAGCCTTACAGCCTCTGCGTCCAGCGTCTGTGATGTTCTGCTATTACCTACATTGTTTGAGCCTCATGAAAACCCCACTGGCTGAGACGCCTACCC 3698
TGCTGGCCTTCTTGCTAGGTGTTCCCAACAGGTCTCTGAGCATCTCTTTCTCTCAACAG OAAA AAG CGG ATG GTG GTC CCT GCT GCT 3784
Lys Lys Arg Met Val Val Pro Ala Ala
CTC AAG GTT GTT CGG CTG AAG CCT ACC AGA AAG
￿
GTAAGCTCTAGGTTACAGGTTAGGCTTGTGAGCCTCAAGACTGGCACATGATG 3870
Leu Lys Val Val Arg Leu Lys Pro Thr Arg Lys
TTCTTATTCTCACGATGGTCTTCGGATGCCACAGTTAGGGCAGTGCCGATAATGCCAAAGGCTAAGCTGATGCCAGGAGGGCTCCCGTGCTGGGGATGA 3969
GTCCTTGAAATAGGGTCCCTAGGCCTCCGGCTCACCCTTGTGCTGCTGGGGCACATTCCATGTCCTTACAGCCTTGTGCCTCTGCAG OTTT GCT 4062
Phe Ala
e
TAC CTG GGG CGT CTG GCG CAT GAG GTC GGG TGG AAG TAC CAG GCA GTG ACA ACC ACT CTG GAG GAG AAA CGG AAG
￿
4137
Tyr Leu Gly Arg Leu Ala His Glu Val Glu Trp
CAA AAG GCC AAG ATG CAC TAT CGG AAG AAG AAG CAG ATC TTG GTGAGGACGGACACTGAGATCCAGGATTAGGGGGGCGCAGGT 4221
Glu Lys Ala Lys Met His Tyr Arg Lys Lys Lys Gln Ile Leu
Lye Tyr Gln Ala Val Thr Thr .Thr Leu Glu Glu
An M13 construct containing the 1.2-kb fragment of the
normal allele was mutated with an oligonucleotide carrying
the mutation . A resulting clone, which carried the mutation
as verified by sequencing, transferred the expression of an-
tigen P198 (Table I) .
Identification ofan Antigenic Peptide Recognized by Anti-P198
CTL . Because of the compelling evidence that most CTL
recognize short peptides bound to class I MHC molecules,
we examined whether synthetic peptides corresponding to
parts of the putative P198 protein could render P815 cells
susceptible to lysisby anti-P198 CTL . In this search, we were
guided by the location of the turn - mutation . Six different
peptides containing the mutated amino acid were tested (Fig.
7) . Peptide P198 - .9-24, which comprised amino acids 9-24
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Lys Arg Lys
ofexon 7, and also various shorter peptides, induced consid-
erable lysis when they were incubated in the presence of
P1.HTR cells. The most active was P198 - .14-24 : a concen-
tration of 0.7 nM produced half of the maximal lysis, which
was reached at a concentration -10 nM (Fig. 8 A) . We
verified that the effect of this peptide was specific: it did not
induce the lysis of P1.HTR cells by a CTL clone directed
against another turn - antigen (data not shown) .
Peptides P198- .15-24 and P198 - .16-24 failed to induce
any lysis of P1.HTR by anti-P198 CTL (Fig. 8A) . We ana-
lyzed the competitive effect of these two peptides. Peptide
P198 - .15-24 inhibited competitively the lysis induced by
peptide P198 - .14-24, indicating that the removal of the ly-
sine in position 14 eliminated the epitope, without eliminat-Table 1 .
￿
Expression ofAntigen P198 after Site-directed Mutagenesis
Fragments corresponding to position 2983-4172 of the gene (Fig . 6) were isolated from cosmids C198.3 .1 and C1.198 .1 and subcloned in
M13tg130 . The fragment isolated from C1.198 .1 was submitted to site-directed mutagenesis to replace the G in position 4114 by A . The con-
structs were cotransfected with pSVtkneo,6 into P1 .HTR .
S The geneticin-resistant transfectants were submitted to a 4-h 51Cr release assay with CTL-P198 :6 at various E/T ratios .
t The geneticin-resistant transfectants were subcloned, and 17 clones were then tested for their lysis by CTL-P198:6 with a visual assay .
ing the ability to bind to the MHC molecule. Peptide
P198 - .16-24 did not compete with peptide P198 - .14-24,
indicating that the tyrosine in position 15 is required forMHC
binding (Fig. 8 B) .
In agreement with antibody inhibition experiments that
indicated that Kd was the restricting element of antigen
P198 (33), we found that DAP cells (H-2k) that had been
transfected with Kd were lysed by anti-P198 CTL in the
presence of the peptide, whereas DAP cells transfected with
Dd or Ld were not lysed (Fig. 9) .
Effect ofthe turn - Mutation.
￿
Synthetic peptide P198+ .14-
24, corresponding to the normal sequence of the gene, did
not induce the lysis of target cells by anti-P198 CTL, even
at very high concentrations (Fig. 8 A). This could be due
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either to the inability ofthe peptide to bind to the class I-pre-
senting molecule, or to the absence of the epitope recognized
by the anti-P198 CTL . To distinguish between these two pos-
sibilities, we performed competition experiments (Fig. 8 B) :
peptide P198+ .14-24 was clearly able to inhibit competi-
tively the lysis induced by homologous peptide P198 - .14-
24, indicating that the P198 turn - mutation does not create
the aggretope for Kd binding, but rather a new epitope . As
a specificity control, we verified that peptide P198+ .14-24
had no inhibitory effect on the lysis of turn - variant P91 by
the relevant CTL clone CTLP91:6 (data not shown) .
We also analyzed the competitive inhibition exerted by pep-
tides P198 - .14-24 and P198+ .14-24 in a heterologous system
involving Kd-restricted CTL clone CW3/701.1 and peptide
Figure 7.
￿
Nucleotide sequence of the first part of exon 7 and corresponding amino acid sequence. The G to A transition of the turn - muta-
tion and the corresponding Ala to Thr change are indicated. Synthetic peptides corresponding to the mutant (P198 - .) and normal (P198* .) se-
quences were tested for their ability to induce the lysis of P1.HTR cells by CTILP198:6 under the conditions described in Fig. 8 A . The concen-
trations indicated produced 50% of the lysis obtained with saturating concentrations of peptides.
Transfected fragments'
Lysis of
cells with
E/T - 3
neol-transfected
anti-P198 CTL#
E/T=1
Clones expressing P198
neo` clones (per/)S
Fragment of C198.3 .1 (origin P198) : A at position 4114 33 17 11/17
Fragment of C1.198.1 (origin P1) : G at position 4114 0 0 0/17
Fragment of C1.198.1 with G4114 replaced by A 38 19 7/1780
a
., 60
r 40
20 -
e
0
Lysis of P1 .HTR calls
10 4 1~'t02 1G1 10o 101 1 "Oa
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1-00
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1.01
102
￿
10-201
1
Concentration of competitor peptide (AM)
HLA-CW3 170-182 (Fig. 8 C) (34). In agreement with the
results obtained for anti-P198 lysis, both were shown to be
effective competitors.
We have isolated the gene that codes for turn - antigen P198.
This antigen was defined as the target of CTL clones specific
for turn - variant P198 . It is also relevant to the rejection of
16'10 1d
￿
102 103 104 ￿102 103 104
￿
161 1CP4
￿
1oz 103 104
Peptide concentration (nM)
Figure 9.
￿
Identification of Kd as presenting molecule for antigen
P198. Lines T483, T191, and T111 were derived from H2k fibroblast
line DAP by transfection with plasmids containing the genes coding
for Dd, Kd, or Ld. 2,000 "Cr-labeled target cells were preincubated
for 45 min with increasing concentrations of peptide P198 - .14-24 be-
fore a 4-h Cr release assay with CTLP198:6 at an E/T ratio of 10:1.
All the target cells, except P1.HTR, were incubated in the presence
of 25% of secondary allogeneic MLC supernatant during the 3 d
preceding the test.
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Figure 8.
￿
Induction of lysis and competition by
synthetic P198 peptides. (A) Lysis of P1.HTR cells
by CTLP198:6 in the presence of increasing concen-
trations of peptides encoded by the mutated or
normal allele of gene P198. s1Cr-labeled cells were
incubated with CTLP198:6 for 4 h at an E/T ratio
of 10:1 in the presence of various concentrations of
the peptides. (B) Comparison of peptides P198' .14-
24, P198- .15-24, and P198- .16-24 as competitors
for peptide P198 - .14-24. "Cr-labeled P1.HTR cells
were preincubated for 15 min at 37°C with in-
creasing concentrations of the competitor peptides
before adding peptide P198 - .14-24 at a concentra-
tion of 6 nM. The cells were then incubated for
4 h with CTLP198:6 at a 10:1 E/T ratio. (C)
Comparison of peptides P198' .14-24 and P198- .14-
24 as competitors for peptide HLA-CW3 170-182
inducing lysis by Kd-restricted CTLCW3/701.1.
The experiment was performed as in B, except that
the CW3 peptide was added at 100 nM and that
the CTL to target ratio was 3 :1.
this turn - variant by syngeneic mice. This could be shown
as follows. Occasionally, mice injected with variant P198 were
found to form progressive tumors, and these tumor cells could
be adapted to culture. These tumor cells were found to be
resistant to lysis by anti-P198 CTL, indicating that the target
antigen of these CTL is also selected against in vivo (10).
The transfection approach, which previously ensured the
cloning of the gene of turn - antigen P91A, proved to be ap-
plicable to antigen P198. Among the P1.HTR cells that had
integrated genomic DNA from the turn - variant, transfec-
tants expressing antigen P198 were found at a frequency of
1113,000. A similar frequency was observed with geneP91A
(13) . Considering that the.mammalian genome comprises ti6
x 106 kb, that turn- mutants are heterozygous for the mu-
tation, and that transfectants are estimated to incorporate
"1,000 kb of DNA (35), the theoretical frequency is 1/6,000.
It appears, therefore, that P1.HTR transfectants express trans-
fected turn - genes efficiently and that detection by CTL
stimulation is also efficient. In the library of 400,000 cosmids
prepared with DNA of variant P198, three were found to
transfer the expression of the antigen. This compares with
2/700,000 for the P91A cosmid library (14). These values
are also close to the theoretical frequency, which is
"1/150,000. The direct recovery of a cosmid carrying the
turn - gene proved to be more arduous for P198 than for
P91A. Direct packaging of one of three cosmid transfectants
produced a major cosmid species carrying gene P91A . For
P198, none of five cosmid transfectants did, and we had to
use a secondary transfectant to obtain a cosmid carrying the
gene. Because direct packaging of a transfected gene requires
insertion of the genebetween two cos sites in the same orien-
Target cells pro-Incubated with peptide P198-.14-24
P1 .HTR
H-2d
DAP
H-2 k
T483
H-2k+Dd
T191
H-2k+Kd
T111
H-2k+Ld
f._.~ _.Za
Itation, and at a distance of40-50 kb, it is not surprising that
only a minority of the cosmid transfectants lend themselves
to direct cosmid recovery. Nevertheless, the results obtained
in the cloning of gene P198 are on the whole very similar
to those obtained with P91A . These and similar results ob-
tained with a third turn - gene (36) show that our approach
should be applicable to many transplantation antigens.
In the course of the cloning of gene P198, we repeated
a surprising observation made with gene P91A . Promoter-
less gene fragments that were cloned in vectors that are not
eucaryotic expression vectors were found to transfer efficiently
the expression of the antigen. This may applyonly to trans-
fected DNA, due for instance to preferential insertion into
the actively transcribed regions. On the other hand, it may
reflect a new mechanism leading to the production of anti-
genic peptides by a translation process that starts shortly be-
fore the region encoding the antigenic peptide (37, 38).
The antigenic allele of gene P198 differs from the normal
allele by a point mutation in exon 7. This mutation is respon-
siblefor the antigenicity, as shown by site-directed mutagen-
esis, and it appears to be the only difference between the two
alleles. A short synthetic peptide corresponding to the se-
quence surrounding the Thr residue introduced by the turn -
mutation was found to render P1 cells sensitive to lysis by
anti-P198 CTL. This demonstrates that gene P198 is the struc-
tural gene of the antigen . A similar situation was reported
for turn - gene P91A, there also, an antigenic peptide was
encoded by the region surrounding the turn - mutation (15).
However, the role of the P198 turn - mutation appears to be
quite different from that of the P91A mutation. For P91A,
the homologous peptide corresponding to the normal sequence
of the gene does not induce lysisof P1 by the anti-P91Á CTL
and does not compete with the antigenic peptide. We con-
cluded that this turn - mutation makes the peptide capable
of binding to the presenting molecule, which is Ld . For an-
tigen P198, the peptide encoded by the normal allele does
not render PI cells sensitive to lysis by the CTL, but it com-
petes with the antigenic peptide for binding to Kd. It ap-
pears, therefore, that the P198 turn - mutation generates a
new epitope on a peptide that is already capable of binding
to the Kd molecule. The normal peptide is presumably not
recognized by the T lymphocytes because of natural tolerance.
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